Epstein-Barr Virus (EBV) VCA, IgM
The Epstein-Barr virus (EBV) is a member of the herpes virus family, and is responsible for many disorders including infectious mononucleosis, and other lymphoproliferative disorders. In young adults, EBV infection may be clinically manifested as infectious mononucleosis with typical symptoms of sore throat, fever, and lymphadenopathy. Following primary EBV infection, virus establishes its latency in B lymphocytes that may extend through life. Reactivation of EBV infection or enhanced EBV activation has been documented in immunodeficient or immunosuppressed patients, i.e., organ transplant patients, individuals with malignancies, in HIV infected patients, pregnant women and persons of advanced age. EBV has also been associated in the pathogenesis of two human cancers, Burkitt’s lymphoma and nasopharyngeal carcinoma. Several reports have suggested that EBV infection is associated with chronic fatigue syndrome.
Most of today’s serology assays to EBV detect antibody to viral capsid antigens (VCA). These are viral structural proteins necessary for its replication. The IgM response to VCA is among the earliest detectable humoral immune responses, usually present at the onset of the disease and peaking within three to six weeks. VCA-IgM levels are also transient, declining rapidly and usually becoming undetectable within two to three months from onset of clinical symptoms. False positive IgM levels have been reported due to cross-reactivity with cytomegalovirus (CMV), toxoplasma and herpes simplex antibodies. Rheumatoid factors may also cause false positive IgM results.
- Diagnostic for a current or acute EBV infection
- Differential diagnosis of EBV re-activation
- As an aid in diagnosis of infectious mononucleosis
- As an aid in diagnosis of Burkitt's lymphoma
- As an aid in diagnosis of nasopharyngeal carcinoma
- As an aid in diagnosis of chronic fatigue syndrome
Positive in:
- Acute EBV infection
- Viral re-activation
- Infectious mononucleosis
- Burkitt's lymphoma
- Nasopharyngeal carcinoma
- Chronic fatigue syndrome
Negative in:
- Latent infection
- Past infection
| Index Value | Interpretation |
| <0.9 | No detectable IgG antibodies to EBV VCA. |
| 0.91-1.09 | Equivocal results – testing should be repeated in 1-2 weeks. |
| >1.10 | Reactive for IgG antibodies to EBV VCA. |
Immunoassay, Enzyme-Linked Immunosorbent Assay (ELISA).
Serum (SST).
Stability
- Ambient: 48 hours
- Refrigerated: 7 days
- Frozen: 60 days
- Virus Res. 2002 Jan 30;82(1-2):109-13. [PMID: 11885937]
- Am Fam Physician. 2004;70:1279. [PMID: 15508538]
- Annu Rev Pathol. 2006;1:375-404. [PMID: 18039120]
- Lancet Infect Dis. 2003 Mar;3(3):131-40. [PMID: 12614729]
- Am J Med. 2007 Oct;120(10):911.e1-8. [PMID: 17904463]
- In Vivo. 2007 Sep-Oct;21(5):707-13. [PMID: 18019402]
- Clin Otolaryngol Allied Sci. 2001 Feb;26(1):3-8. [PMID: 11298158]
- Stevens,Christine Dorresteyn. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company. 2010.
- EBV early antigen (EA) ELISA II package insert. Wampole laboratories ref. 425000CE 06/2005